Sponsor Dossier
Southern Cross Pharma
Sponsor Dossier for Southern Cross Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AGOMELATINE
- Brand: AMISULPRIDE
- Brand: AMOXYCLAV DUO
- Brand: ANAGRELIDE
- Brand: ANASTROZOLE
- Brand: APO-AGOMELATINE
- Brand: APO-CLONIDINE
- Brand: APO-FENOFIBRATE
About
Southern Cross Pharma is an Australian Private Company with ABN 47094447677, registered in Victoria and currently active.
Portfolio
Southern Cross Pharma maintains 82 brands on the ARTG, of which 51 are indexable. The portfolio includes 46 brands with Product Information on file, 5 brands with PBS-listed items, 4 brands with PBAC outcomes on record, and 1 brand with an AusPAR.
Therapeutic focus —
Neurology: 16 brands — Oncology: 15 brands — Infectious Disease: 14 brands — Cardiology: 9 brands — Gastroenterology: 6 brands — Dermatology: 6 brands — Urology: 3 brands — Haematology: 2 brands — Endocrinology: 2 brands — Immunology: 2 brands — Pain & Anaesthesia: 2 brands — Women's Health: 2 brands — Psychiatry: 1 brand — Uncategorised: 2 brands
PBS footprint
Southern Cross Pharma has 5 brands with at least one PBS-listed item, with the portfolio's latest schedule date being 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Southern Cross Pharma was recorded on 1 July 2024, with 4 brands holding PBAC outcomes on record. The most recent AusPAR was issued on 6 October 2016 for 1 brand.